4142:TPE
Adimmune Corp
16,80Â NT$
arrow_upward
+0,60%(+0,100) 1 p
13. nov, 13:30:11 GMT +8 · TWD
search
Kõik sümbolid
| Sümbol | Hind | Muutus | % muutus |
|---|
insights_autoÜksuse 4142 põhistatistika genereerimine…
Ava
16,85Â NT$
Kõrge
17,15Â NT$
Madal
16,75Â NT$
Turu kapit.
7,22Â mld
Keskm. maht
1,13Â mln
Maht
724,64Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
15,65Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Ava
16,85Â NT$
Kõrge
17,15Â NT$
Madal
16,75Â NT$
Turu kapit.
7,22Â mld
Keskm. maht
1,13Â mln
Maht
724,64Â tuh
52 näd kõrgeim
22,50Â NT$
52 näd madalaim
15,65Â NT$
Aktsiatulu
−0,34 NT$
Käibivad aktsiad
235,29Â mln
Töötajate arv
564
Uudised
Veebiallikatest ja uudistepartneritelt
Yahoo! Finance Canada
·
22 minuti eest
AMN,HLF,BSBK,FXNC,IMRX,MRBK,FRST,TISI,GRNT,TPL,FTHM,VSTS,RVSB,GEF-B,BCRX,TMCI,SABR,SHEN,DCGO,NBBK,USCB | Stock Prices | Quote Comparison - Yahoo Finance
Bloomberg.com
·
18 tunni eest
SpaceX’s S&P 500 Bid Gets New Life as Musk Pitches Tesla Merger
AP News
·
1 päeva eest
Microsoft outage shows the risks of relying on a single technology provider for essential services
Investor's Business Daily
·
4 tunni eest
Futures Loom As Bitcoin Dives In Shaky Rally. What To Do Now.
Profiil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Teave üksuse Adimmune Corp kohta